Bachir Bassel G, Aprikian Armen G, Fradet Yves, Chin Joseph L, Izawa Jonathan, Rendon Ricardo, Estey Eric, Fairey Adrian, Cagiannos Ilias, Lacombe Louis, Lattouf Jean-Baptiste, Bell David, Saad Fred, Drachenberg Darrel, Kassouf Wassim
Department of Surgery (Urology), McGill University, Montreal, QC;
Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E667-72. doi: 10.5489/cuaj.201.
Our objective is to assess differences in practice patterns and outcomes across 3 regions in bladder cancer patients treated with radical cystectomy under a universal healthcare system.
In total, we included 2287 patients treated with radical cystectomy at 8 Canadian centres from 1998 to 2008. Variables included various clinico-pathologic parameters, recurrence, and death stratified into different regions.
In total, 1105 patients were from the east region (group 1), 601 from the centre region (group 2), and 581 from the west region of Canada (group 3). The median follow-up of groups 1, 2, and 3 was 22.1, 17.1, and 28.6 months, respectively. Although the overall rate of neoadjuvant chemotherapy was low (3.1%), rates were higher in group 2 compared with groups 1 and 3 (p = 0.07). Continent diversions and extended lymphadenectomy were performed in 23.5%, 8.5%, 23.9% and 39.7%, 27.7%, 12.6% across groups 1, 2, and 3, respectively. There were statistically significant differences in gender distribution, performance of lymphadenectomy, presence of concomitant carcinoma in situ and lymphovascular invasion across the 3 groups. There were no differences among the 3 geographical locations in terms of stage, surgical margin status, and use of adjuvant chemotherapy. The mean number of days from the transurethral resection of the bladder tumour to cystectomy was 50, 79, 69 days for groups 1, 2, 3, respectively (p = 0.0006). The 5-year overall survival was 53.6%, 66.8%, and 52.4% for groups 1, 2 and 3, respectively (p < 0.0001).
Significant variations in practice patterns were noted across different geographic regions in a universal healthcare system. Use of continent diversions, extended lymphadenectomy, and neoadjuvant chemotherapy remains low across all 3 regions. Treatment delays are significant.
我们的目标是评估在全民医疗保健系统下接受根治性膀胱切除术的膀胱癌患者在三个地区的治疗模式和治疗结果的差异。
我们总共纳入了1998年至2008年在加拿大8个中心接受根治性膀胱切除术的2287例患者。变量包括各种临床病理参数、复发情况以及按不同地区分层的死亡情况。
总共有1105例患者来自东部地区(第1组),601例来自中部地区(第2组),581例来自加拿大西部地区(第3组)。第1组、第2组和第3组的中位随访时间分别为22.1个月、17.1个月和28.6个月。虽然新辅助化疗的总体使用率较低(3.1%),但第2组的使用率高于第1组和第3组(p = 0.07)。第1组、第2组和第3组分别有23.5%、8.5%、23.9%的患者接受了可控性尿流改道术,分别有39.7%、27.7%、12.6%的患者接受了扩大淋巴结清扫术。三组在性别分布、淋巴结清扫术的实施情况、伴发原位癌的存在情况以及淋巴管侵犯方面存在统计学上的显著差异。在分期、手术切缘状态和辅助化疗的使用方面,三个地理位置之间没有差异。第1组、第2组、第3组从经尿道膀胱肿瘤切除到膀胱切除术的平均天数分别为50天、79天、69天(p = 0.0006)。第1组、第2组和第3组的5年总生存率分别为53.6%、66.8%和52.4%(p < 0.0001)。
在全民医疗保健系统中,不同地理区域的治疗模式存在显著差异。在所有三个地区,可控性尿流改道术、扩大淋巴结清扫术和新辅助化疗的使用率仍然较低。治疗延迟情况显著。